Ritzerfeld W
Infection. 1979;7 Suppl 4:S342-4. doi: 10.1007/BF01639010.
Co-trimazine, a new combination of trimethoprim and sulphadiazine intended for treatment of urinary tract infections, was tested and compared to co-trimoxazole in an experimental model of acute, obstructive pyelonephritis in the rat. The tests were carried out at four dose levels corresponding to the clinically recommended doses and to 1/4, 1/2, and 3/4 of the latter. The drugs were administered orally. Co-trimazine was found to have a greater antibacterial activity than co-trimoxazole and its use at a lower dosage than that of the latter appears warranted.
复方磺胺嘧啶,一种用于治疗尿路感染的新的甲氧苄啶与磺胺嘧啶的组合,在大鼠急性梗阻性肾盂肾炎的实验模型中进行了测试,并与复方新诺明进行了比较。测试在四个剂量水平进行,分别对应临床推荐剂量以及后者的1/4、1/2和3/4。药物通过口服给药。结果发现复方磺胺嘧啶比复方新诺明具有更强的抗菌活性,而且似乎有必要以低于复方新诺明的剂量使用它。